

HASTANEDE ANTİMİKROBİYAL TÜKETİMİN ÖLÇÜLMESİ

Uzm.Ecz.Aslı Özyıldırım

Koç Sağlık Grubu Eczane Direktörü

Asli Ozyildirim, Bpharm, MSc

Koc Healthcare Chief of Pharmacy

ATC (*Anatomical Therapeutic Chemical*)

- Aktif maddeler farklı gruplara ayrılır:
 - Etki ettikleri organ / sistem
 - Terapötik özellikler
 - Farmakolojik özellikler
 - Kimyasal özellikler



ATC (1.Seviye)

14 Ana Grup
(Anatomik&Farmakolojik)
5 seviye

Code	Contents
A	Alimentary tract and metabolism
B	Blood and blood forming organs
C	Cardiovascular system
D	Dermatologicals
G	Genito-urinary system and sex hormones
H	Systemic hormonal preparations, excluding sex hormones and insulins
J	Antiinfectives for systemic use
L	Antineoplastic and immunomodulating agents
M	Musculo-skeletal system
N	Nervous system
P	Antiparasitic products, insecticides and repellents
R	Respiratory system
S	Sensory organs
V	Various

ATC (2.Seviye)

The screenshot displays the website of the WHO Collaborating Centre for Drug Statistics Methodology, which is part of the Norwegian Institute of Public Health. The page features a header with the WHO logo and the text 'WHO Collaborating Centre for Drug Statistics Methodology' and 'Norwegian Institute of Public Health'. Below the header, there is a navigation menu on the left with links to 'News', 'ATC/DDD Index', 'Updates included in the ATC/DDD Index', 'ATC/DDD methodology', 'ATC', 'DDD', 'ATC/DDD alterations, cumulative lists', 'ATC/DDD Index and Guidelines', 'Use of ATC/DDD', 'Courses', 'Meetings/open session', 'Deadlines', and 'Links'. The main content area shows the 'ATC/DDD Index' with a list of drug classes: 'ANTIINFECTIVES FOR SYSTEMIC USE', 'ANTIBACTERIALS FOR SYSTEMIC USE', 'ANTIMYCOTICS FOR SYSTEMIC USE', 'ANTIMYCOBACTERIALS', 'ANTIVIRALS FOR SYSTEMIC USE', 'IMMUNE SERA AND IMMUNOGLOBULINS', and 'VACCINES'. A 'New search' button and a 'Show text from Guidelines' link are also visible. The page is last updated on 2018-12-13. At the bottom, there is a postal address and a visiting/delivery address in Oslo, Norway.

WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health

News
ATC/DDD Index
Updates included in the ATC/DDD Index
ATC/DDD methodology
ATC
DDD
ATC/DDD alterations, cumulative lists
ATC/DDD Index and Guidelines
Use of ATC/DDD
Courses
Meetings/open session
Deadlines
Links

Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

ANTIINFECTIVES FOR SYSTEMIC USE
001 ANTIBACTERIALS FOR SYSTEMIC USE
002 ANTIMYCOTICS FOR SYSTEMIC USE
004 ANTIMYCOBACTERIALS
005 ANTIVIRALS FOR SYSTEMIC USE
006 IMMUNE SERA AND IMMUNOGLOBULINS
007 VACCINES

New search Show text from Guidelines

Last updated: 2018-12-13

Farmasötik ve
Terapötik gruplar

ATC (3. ve 4. Seviye)

Kimyasal, Farmasötik
ve Terapötik alt gruplar

WHO Collaborating Centre for
Drug Statistics Methodology

Norwegian Institute of Public Health

News

ATC/DDD Index

Updates included in the
ATC/DDD Index

ATC/DDD methodology

ATC

DDD

ATC/DDD alterations,
cumulative lists

ATC/DDD Index and
Guidelines

Use of ATC/DDD

Courses

Meetings/open session

Deadlines

Links

Postal address:
WHO Collaborating Centre
for Drug Statistics
Methodology
Norwegian Institute of
Public Health
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

[New search](#) [Show text from Guidelines](#)

J01 ANTIINFECTIVES FOR SYSTEMIC USE

J01M QUINOLONE ANTIBACTERIALS

J01MA **Fluoroquinolones**

J01MB **Other quinolones**

Last updated: 2018-12-13

ATC (5.Seviye)



WHO Collaborating Centre for
Drug Statistics Methodology



Norwegian Institute of
Public Health

[New search](#) [Show text from Guide](#)

[ATC/DDD Index](#)
[Updates included in the ATC/DDD Index](#)
[ATC/DDD methodology](#)
[ATC](#)
[DDD](#)
[ATC/DDD alterations, cumulative lists](#)
[ATC/DDD Index and Guidelines](#)
[Use of ATC/DDD](#)
[Courses](#)
[Meetings/open session](#)
[Deadlines](#)
[Links](#)

Postal address:
WHO Collaborating Centre
for Drug Statistics
Methodology
Norwegian Institute of
Public Health
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel: +47 21 07 81 60

J ANTIINFECTIVES FOR SYSTEMIC USE
J01 ANTIBACTERIALS FOR SYSTEMIC USE
J01M QUINOLONE ANTIBACTERIALS
J01MA Fluoroquinolones

ATC code	Name
J01MA01	ofloxacin
J01MA02	ciprofloxacin
J01MA03	pefloxacin
J01MA04	enoxacin
J01MA05	temafloxacin
J01MA06	norfloxacin
J01MA07	lomefloxacin
J01MA08	fleroxacin
J01MA09	sparfloxacin
J01MA10	rufloxacin
J01MA11	grepafloxacin
J01MA12	levofloxacin
J01MA13	trovafloxacin
J01MA14	moxifloxacin
J01MA15	gemifloxacin
J01MA16	gatifloxacin

Etken madde

ATC (*Anatomical Therapeutic Chemical*)

- İki veya daha fazla dozda veya açıkça farklı terapötik kullanımlara sahip uygulama yollarında mevcutsa, bir tıbbi maddeye birden fazla ATC kodu verilebilir
 - Finasterid:
 - Erkek tipi kellik tedavisi için düşük mukavemetli bir tablet D11AX - Diğer dermatolojikler altında sınıflandırılmıştır.
 - Benign prostat hipertrofisinin (BPH) tedavisinde kullanılan yüksek mukavemetli bir tablet, G04C - BPH'de kullanılan ilaçlar altında sınıflandırılmıştır

ATC (*Anatomical Therapeutic Chemical*)

- Tek bileşenli ürünlerde Prednisolone, farklı terapötik kullanım ve farklı formülasyonlar nedeniyle birkaç ATC kodu verilir.
 - A07EA01 Intestinal antiinflammatory agents (enemas and foams)
 - C05AA04 Antihemorrhoidals for topical use (suppositories)
 - D07AA03 Dermatological preparations (creams, ointments and lotions)
 - H02AB06 Corticosteroids for systemic use (tablets, injections)
 - R01AD02 Nasal decongestants (nasal sprays/drops)
 - S01BA04 Ophthalmologicals (eye drops)
 - S02BA03 Otologicals (ear drops)

ATC (*Anatomical Therapeutic Chemical*)



WHO Collaborating Centre for
Drug Statistics Methodology



Norwegian Institute of Public Health

News

ATC/DDD Index

Updates included in the
ATC/DDD Index

ATC/DDD methodology

ATC

DDD

ATC/DDD alterations,
cumulative lists

ATC/DDD Index and
Guidelines

Use of ATC/DDD

Courses

Meetings/open session

Deadlines

Links

Postal address:
WHO Collaborating Centre
for Drug Statistics
Methodology
Norwegian Institute of
Public Health
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

New search

Found 7 entries containing 'naprox'.

M01AE18	naproxcinod
G02CC02	naproxen
M01AE02	naproxen
M01AE02	naproxen
M02AA12	naproxen
M01AE52	naproxen and esomeprazole
M01AE56	naproxen and misoprostol

Last updated: 2018-12-13

ATC (*Anatomical Therapeutic Chemical*)

The screenshot displays the website of the WHO Collaborating Centre for Drug Statistics Methodology, which is part of the Norwegian Institute of Public Health. The page features a navigation menu on the left with links to News, ATC/DDD Index, Updates included in the ATC/DDD Index, ATC/DDD methodology, ATC, DDD, ATC/DDD alterations, cumulative lists, ATC/DDD Index and Guidelines, Use of ATC/DDD, Courses, Meetings/open session, Deadlines, and Links. The main content area shows the ATC/DDD Index for G02C, with a table listing drugs and their DDD values. The table has columns for ATC code, Name, DDD, U, Adm.R, and Note. The first entry is G02CC02, naproxen, with a DDD of 250 mg. The page also includes a 'New search' button, a 'Show text from Guidelines' button, a 'List of abbreviations' link, and a 'Last updated: 2018-12-13' date.

WHO Collaborating Centre for
Drug Statistics Methodology

Norwegian Institute of Public Health

News

ATC/DDD Index

Updates included in the
ATC/DDD Index

ATC/DDD methodology

ATC

DDD

ATC/DDD alterations,
cumulative lists

ATC/DDD Index and
Guidelines

Use of ATC/DDD

Courses

Meetings/open session

Deadlines

Links

Postal address:
WHO Collaborating Centre
for Drug Statistics
Methodology
Norwegian Institute of
Public Health
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

New search Show text from Guidelines

G GENITO URINARY SYSTEM AND SEX HORMONES
G02 OTHER GYNECOLOGICALS
G02C OTHER GYNECOLOGICALS
G02CC Antiinflammatory products for vaginal administration

ATC code	Name	DDD	U	Adm.R	Note
G02CC02	naproxen	250 mg			

List of abbreviations

Last updated: 2018-12-13

ATC (*Anatomical Therapeutic Chemical*)



WHO Collaborating Centre for
Drug Statistics Methodology



Norwegian Institute of Public Health

[News](#)
ATC/DDD Index
[Updates included in the ATC/DDD Index](#)
[ATC/DDD methodology](#)
[ATC](#)
[DDD](#)
[ATC/DDD alterations, cumulative lists](#)
[ATC/DDD Index and Guidelines](#)
[Use of ATC/DDD](#)
[Courses](#)
[Meetings/open session](#)
[Deadlines](#)
[Links](#)

[New search](#) [Show text from Guidelines](#)

M MUSCULO-SKELETAL SYSTEM
M01 ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01AE Propionic acid derivatives

ATC code	Name	DDD	U	Adm.R	Note
M01AE02	naproxen	0.5	g	O	
		0.5	g	R	

[List of abbreviations](#)

Last updated: 2018-12-13

Postal address:
WHO Collaborating Centre
for Drug Statistics
Methodology
Norwegian Institute of
Public Health
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

ATC (*Anatomical Therapeutic Chemical*)

The screenshot shows the website of the WHO Collaborating Centre for Drug Statistics Methodology, which is part of the Norwegian Institute of Public Health. The left sidebar contains a navigation menu with the following items: News, ATC/DDD Index, ATC/DDD methodology, **ATC** (highlighted with a red circle), Structure and principles, Application for ATC codes, Application for ATC alterations, Application form, Lists of new ATC/DDDs and alterations, DDD, ATC/DDD alterations, cumulative lists, ATC/DDD Index and Guidelines, Use of ATC/DDD, Courses, Meetings/open session, Deadlines, and Links. The main content area is titled "Structure and principles" and contains a section on the "Structure" of the ATC classification system. It explains that active substances are classified in a hierarchy with five levels: anatomical/pharmacological groups (1st level), therapeutic subgroups (2nd level), chemical, pharmacological or therapeutic subgroups (3rd and 4th levels), and the chemical substance (5th level). A table illustrates the classification of metformin, showing the hierarchy from the 1st level (A) to the 5th level (A10BA02). A "Contents" sidebar on the right lists various topics related to the ATC system, including Structure, Nomenclature, Inclusion and exclusion criteria, Therapeutic use or pharmacological class, and more.

WHO Collaborating Centre for Drug Statistics Methodology

Norwegian Institute of Public Health

Structure and principles

Structure

In the ATC classification system, the active substances are classified in a hierarchy with five different levels. The system has fourteen main anatomical/pharmacological groups or 1st levels. Each ATC main group is divided into 2nd levels which could be either pharmacological or therapeutic groups. The 3rd and 4th levels are chemical, pharmacological or therapeutic subgroups and the 5th level is the chemical substance. The 2nd, 3rd and 4th levels are often used to identify pharmacological subgroups when that is considered more appropriate than therapeutic or chemical subgroups. The complete classification of metformin illustrates the structure of the code:

A	Alimentary tract and metabolism (1st level, anatomical main group)
A10	Drugs used in diabetes (2nd level, therapeutic subgroup)
A10B	Blood glucose lowering drugs, excl. insulins (3rd level, pharmacological subgroup)
A10BA	Biguanides (4th level, chemical subgroup)
A10BA02	metformin (5th level, chemical substance)

Thus, in the ATC system all plain metformin preparations are given the code A10BA02.

Nomenclature [\(to the top\)](#)

Contents

- [Structure](#)
- [Nomenclature](#)
- [Inclusion and exclusion criteria](#)
- [Therapeutic use or pharmacological class](#)
- [Only one ATC code for each route of administration](#)
- [More than one ATC code for a medicinal substance](#)
- [New ATC groups and "other" groups \(X groups\)](#)
- [Other general principles](#)
- [Classification of combination products](#)

Postal address:
WHO Collaborating Centre
for Drug Statistics
Methodology
Norwegian Institute of

DDD (*Defined Daily Dose-Tanımlanmış Günlük Doz*)


- Yetişkinlerde ana endikasyonda kullanılan bir ilaç için günlük ortalama bakım dozu
- DDD bir ölçüm birimidir, önerilen ya da reçete edilen dozu yansıtmaz
- Hastaların bireysel farklılıklarından (yaş, ağırlık, etnik köken, cinsiyet..) bağımsızdır
- İlaç tüketimin kabaca hesaplanması esasına dayanır
- İlacın satış fiyatı ya da ambalaj içeriğinden bağımsız bir değerdir

DDD (*Defined Daily Dose-Tanımlanmış Günlük Doz*)

- Ortak payda da buluşmayı sağlayan karşılaştırma ölçütüdür
- İstisnai durumlar
 - Nadir hastalıklar
 - Yüksek derecede bireysel dozlar
 - Topikal preparatlar
 - Aşılar
 - Kemoterapi ajanları
 - Lokal anestezipler
 - Allerjenler

DDD (*Defined Daily Dose-Tanımlanmış Günlük Doz*)

- Çoklu etken maddeler**
- Parenteral dozlar** (Aynı DDD)



The screenshot displays the website of the WHO Collaborating Centre for Drug Statistics Methodology, specifically the 'Definition and general considerations' page for the Defined Daily Dose (DDD). The page is organized into a header, a left sidebar, a main content area, and a right sidebar.

Header: The top of the page features the WHO logo and the text 'WHO Collaborating Centre for Drug Statistics Methodology' on the left, and the 'Norwegian Institute of Public Health' logo on the right.

Left Sidebar: A vertical menu lists various resources. The 'DDD' link is highlighted with a red circle. Other items include 'News', 'ATC/DDD Index', 'ATC/DDD methodology', 'ATC', 'Definition and general considerations', 'Application for DDD', 'Application for DDD alterations', 'Application form', 'Lists of new ATC/DDDs and alterations', 'List of DDDs combined products', 'List of DDDs herbals', 'List of DDDs for 3 years revision', 'ATC/DDD alterations, cumulative lists', 'ATC/DDD Index and Guidelines', 'Use of ATC/DDD', 'Courses', 'Meetings/open session', and 'Deadlines'.

Main Content Area: The title 'Definition and general considerations' is prominently displayed. Below it, the 'Definition and introduction' section states: 'The basic definition of the defined daily dose (DDD) is: The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults.' It further explains that the DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. It also notes that only one DDD is assigned per ATC code and route of administration.

Right Sidebar: A 'Contents' section lists the following topics: 'Definition and introduction', 'General principles for DDD assignment', and 'DDDs for combinations products'.

ATC/DDD

WHO Collaborating Centre for Drug Statistics Methodology

Norwegian Institute of Public Health

News

ATC/DDD Index

Updates included in the ATC/DDD Index

ATC/DDD methodology

ATC

DDD

ATC/DDD alterations, cumulative lists

ATC/DDD Index and Guidelines

Use of ATC/DDD

Courses

Meetings/open session

Deadlines

Links

Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

3 **ANTIINFECTIVES FOR SYSTEMIC USE**
J01 **ANTIBACTERIALS FOR SYSTEMIC USE**
J01D **OTHER BETA-LACTAM ANTIBACTERIALS**
J01DH **Carbapenems**

ATC code Name DDD U Adm.R Note

J01DH02 meropenem 3 g P

[List of abbreviations](#)

Last updated: 2018-12-13

New search Show text from Guidelines

WHO Collaborating Centre for Drug Statistics Methodology

Norwegian Institute of Public Health

News

ATC/DDD Index

Updates included in the ATC/DDD Index

ATC/DDD methodology

ATC

DDD

ATC/DDD alterations, cumulative lists

ATC/DDD Index and Guidelines

Use of ATC/DDD

Courses

Meetings/open session

Deadlines

Links

Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

3 **ANTIINFECTIVES FOR SYSTEMIC USE**
J01 **ANTIBACTERIALS FOR SYSTEMIC USE**
J01C **BETA-LACTAM ANTIBACTERIALS, PENICILLINS**
J01CA **Penicillins with extended spectrum**

ATC code Name DDD U Adm.R Note

J01CA01 ampicillin 2 g O
6 g P
2 g R

J01CA02 pivampicillin 1.05 g O

J01CA03 carbenicillin 12 g P

J01CA04 amoxicillin 3 g P
1.5 g O

J01CA05 carindacillin 4 g O

J01CA06 bacampicillin 1.2 g O

J01CA07 epicillin 2 g O
2 g P

J01CA08 pivmecillinam 0.6 g O

J01CA09 azlocillin 12 g P

J01CA10 mezlocillin 6 g P

J01CA11 mecillinam 1.2 g P

J01CA12 piperacillin 14 g P

J01CA13 ticarcillin 15 g P

J01CA14 metampicillin 1.5 g O
1.5 g P

J01CA15 talampicillin 2 g O

J01CA16 sulbenicillin 15 g P

J01CA17 temocillin 4 g P

J01CA18 hetacillin 2 g O

New search Show text from Guidelines

AT (*Antibiyotik Tüketim İndeksi*)

$$DDD = \frac{\text{Number of Units} \times \text{Amount of drug per unit}}{DDD \text{ of the drug}}$$

in general we express hospital consumption as a use density :

$$DDD/100 \text{ hospital-days} = \frac{\text{number of daily doses} \times 100}{\text{number of care days}}$$

as only use density allows comparisons

— — —

AT (*Antibiyotik Tüketim İndeksi*)

- Meropenem

- DDD: 3 (WHO)
- Aylık Tüketim (Ocak): 2530 kutu
- Hasta yatış gün sayısı (Ocak): 5954
- 1000 hasta gününde kullanılan meropenem kutu miktarı:
$$(Aylık\ Tüketim \times 1000) / Hasta\ yatış\ gün\ sayısı$$
$$(2530 \times 1000) / 5954 = 425$$

- AT:

$$(1000\ hasta\ gününde\ kullanılan\ meropenem\ kutu\ miktarı / DDD)$$
$$425 / 3 = \underline{142}$$

AT (*Antibiyotik Tüketim İndeksi*)

- Seftriakson

- DDD: 2 (WHO)
- Aylık Tüketim (Ocak): 910 kutu
- Hasta yatış gün sayısı (Ocak): 5954
- 1000 hasta gününde kullanılan seftriakson kutu miktarı:
$$(Aylık\ Tüketim \times 1000) / Hasta\ yatış\ gün\ sayısı$$
$$(910 \times 1000) / 5954 = 153$$

- AT:

$$(1000\ hasta\ gününde\ kullanılan\ seftriakson\ kutu\ miktarı / DDD)$$
$$153 / 2 = \underline{76}$$

RDD vs PDD

Multiple definitions and indicators


- DDD (Defined Daily Dose) : Assumed average maintenance dose per day for a drug used for its main indication in adults. (www.whocc.no). *Unrealistic (overestimation) but useful for international comparisons.*
- PDD (Prescribed Daily dose) : *Preferable!!!*
- RDD (Recommended Daily Dose) (www.antiinfektiva-surveillance.de) : *The German touch : Realistic but very “local”.*

	Günlük Uygulama Dozu	Günde Kaç Kutu Abx. Kullanılıyor	Ocak N:Tüketilen Antibiyotik Kutu Sayısı	Bir ay içinde 1000 hasta gününde Kullanılan anb. Kutu sayısı Miktarı	Ocak Ayı DDD
Meropenem	3x1 gr	3	2530	425	142
Sefazolin	3x1 gr	3	1530	257	86
Ampisilin+Sulbaktam	4x1 gr	4	460	77	19
Seftriakson	2x1 gr	2	910	153	76
Metronidazole	3x0,5 gr	3	430	72	24
Vancomisin	2x1 gr	2	326	55	27
Siprofloksasin	2x 0,2 gr	2	296	50	25
Sefuroksim	3x0,75 gr	3	582	98	33
Flukonazol	1x50 ml	1	78	13	13
Teicoplanin	1x 0,4 gr	1	322	54	54
Piperasilin-tazobactam	3x4.5 gr	1	333	56	56
Trimetoprim sulfametoksazol	2x80 mg	2	15	3	1
Levofloksasin	1 x 0,5 gr	1	218	37	37
Tigesiklin	1 x 0,1 gr	1	181	30	30
Kolistin	2 x 0,15gr	2	22	4	2
Ertapenem	2x1 gr	1	211	35	35
Toplam Yatan Hasta Sayısı			1688		
Toplam Hasta Yatış Günü			5954		

..... Hasta yatış gününde Kutu Antibiyotik kullandı ise 1000 hasta günündex.... kutu antibiyotik kullanmıştır?					
x kutu antibiyotik / DDD = y (gün sayısı kadar antibiyotik kullanılmıştır)					
1000 hasta gününde y gün sayısı kadar antibiyotik kullanılmıştır.					


Antibiyotik Tüketimi (AT)

2017 - 2018-2019 İlk YARI DÖNEM Tüketilen Abx. Miktarı




Antibiyotik Tüketimi (AT)

1. Çeyrek - 2. Çeyrek - 3. Çeyrek (Temmuz ve Ağustos) 2019 Antibiyotik Tüketimi




Meropenem AT Sonuçları


2019 Aylara Göre Tüketilen Meropenem Miktarı



2017-2018-2019 İlk Yarı Dönem Tüketilen Meropenem Miktarı



Meropenem Tüketimi (DDD) 2015-2016-2017-2018-2019



Meropenem Survey - Veri Toplama Formu

ik kamu	ilgi trans akıy	koah/ast	sinir	key	transfuz	Yaş Tarihi	ab başlama tarihi	bitiş tarihi	ampirik, a, etkine yön e	toplum kaynaklı/sbi	meropenem başlama endikay	kültürde üreme var mı? e/h	kan kültürü	Tarih	idrar kültü	Tarih	balgam kültürü	Tarih	diğer	Tarih	CRP1 ()	PCT1 (ng)	Lökosit1 (K)	GFR (ml)	endikay nu u m	endikay nu u m	süre uygu
0	0	0	0	0	0	27.01.2019	24.02.2019	3.03.2019	a	sbi	FEN	UD	UD	UD	UD	UD	UD	UD	UD	UD	106	0,73	25,7	UD	1	1	1
0	0	0	0	0	0	1.03.2019	1.03.2019	4.03.2019	a	tk	sistit	H	UD	UD	Üreme yok	1.03.2019	UD	UD	UD	UD	101	UD	15	UD	0	UD	UD
0	0	1	0	0	0	26.02.2019	28.02.2019	28.02.2019 (EX)	a	tk	pnömoni	E	Staflokok	28.02.2019	UD	UD	Staflokok	28.02.2019	UD	UD	195,3	UD	UD	18,51	0	UD	UD
0	0	0	0	1	0	13.02.2019	13.02.2019	20.02.2019	a	tk	pnömoni	H	Üreme yok	13.02.2019	Üreme yok	14.02.2019	UD	UD	UD	UD	58,3	UD	7,8	46,27	0	UD	UD
0	0	0	0	0	0	11.02.2019	11.02.2019	15.02.2019	a	tk	kolesistit	E	UD	UD	C.kefyr	11.02.2019	UD	UD	UD	UD	18,5	0,06	10,6	90	0	UD	UD
0	0	0	0	0	0	18.02.2019	18.02.2019	25.02.2019	a	tk	pnömoni	UD	UD	UD	UD	UD	UD	UD	UD	UD	73,3	UD	6,8	UD	0	UD	UD
0	0	1	0	0	0	10.02.2019	10.02.2019	18.02.2019	a	tk	selülit	UD	UD	UD	UD	UD	UD	UD	UD	UD	UD	UD	UD	UD	UD	UD	
0	0	0	0	0	0	11.02.2019	11.02.2019	3.03.2019	a	tk	prostatit	UD	UD	UD	Üreme yok	15.02.2019	UD	UD	UD	UD	12	0,05	8,3	UD	0	UD	UD
0	0	0	0	0	0	19.02.2019	19.02.2019	23.02.2019	a	tk	profilaksi (KT sonrası)	UD	UD	UD	UD	UD	UD	UD	diğer Üreme yok	19.02.2019	60,8	UD	5	60,12	0	UD	UD
0	0	1	0	0	1	31.01.2019	8.02.2019	20.02.2019	a	sbi	cerrahi alan, pnömoni	E	UD	UD	Candida albicans	31.01.2019	Üreme yok	31.01.2019	UD	UD	122,4	UD	11,1	164,61	1	1	1
0	0	1	0	1	1	21.12.2018	11.02.2019	10.03.2019	a	sbi	pnömoni	E	Üreme yok	10.02.2019	UD	5.01.2019	E.coli	10.02.2019	Üreme yok (diyaliz katater ucu)	10.02.2019	137,5	UD	7,5	18,23	1	0	0
0	0	1	0	1	0	2.01.2019	4.02.2019	18.02.2019	a	tk	pnömoni	UD	UD	UD	UD	UD	UD	UD	UD	UD	4,7	0,07	13	64,21	0	UD	UD
0	0	0	0	0	0	31.01.2019	5.02.2019	18.02.2019	a	sbi	pnömoni	H	Üreme yok	3.02.2019	Üreme yok	3.02.2019	Üreme yok	5.02.2019	UD	UD	58	UD	14,4	84,96	1	1	1
0	0	1	0	1	0	28.12.2019	11.02.2019	14.02.2019	a	sbi	pnömoni	E	UD	UD	UD	UD	Pseudomonas aeruginosa, Klebsiella pneumoniae, metisiline duyarlı S.aureus	16.01.2019	UD	UD	149	1,29	10,2	UD	1	1	1
0	0	1	0	0	0	14.01.2019	8.02.2019	21.02.2019	a	tk	GDB	UD	UD	UD	UD	UD	UD	UD	UD	UD	43,5	UD	8,4	119,42	0	UD	UD

Meropenem Survey - Veri Toplama Formu

Hastaya Ait Bilgiler

- Ad soyad
- Protokol
- Oda
- Primer Hekim
- Varsa Enf. Hekimi
- Primer Tanı
- Yatış Tarihi
- Cerrahi Operasyon Geçirdi Mi?
- Antibiyotik Alerjisi Var Mı?
- Ko-morbidite
 - Diyabet, KBY, KOAH/Astım, Siroz, KKY
 - Solid Organ Tm (Remisyon, Aktif, Metsatetik)
 - Hematolojik Kanser (Remisyon, Aktif)
 - Kemik İligi Transplantasyonu

Değerlendirme

- Antibiyotik Başlama Tarihi
- Meropenem başlama endikasyonu
- Kültürde üreme var mı?
- Kan, idrar, balgam ve diğer kültürler
- Kültürde üreme varsa rapor tarihi
- Antibiyotik kesme tarihi
- CRP (mg/L)
- PCT (ng/mL)
- Lökosit (K/uL)
- GFR (ml/dk)



Sonuç


- Başlama endikasyonu uygun mu?
- Devam endikasyonu uygun mu?
- Süre uygun mu?

Meropenem Survey – Eczane Sonuçları


12 Şubha

87 hasta


Başlama endikasyonunun durumu
(n=101)




Devam endikasyonu durumu
(n=65)



Kullanım süresi durumu (n=56)




Başlama nedeni (n=101)




Meropenem Survey – Eczane Sonuçları

İlaca başlayan hekim




İlaca başlayan hekim (%)



Meropenem Survey – Eczane Sonuçları

İlaça Uygunsuz Başlayan Bölüm



N:36 adet uygunsuz Meropenem kullanımı bulunmaktadır. Bu veriye göre Meropenem başlama uygunsuzluğu şu şekildedir;

Enfeksiyon Hastalıkları'nın Konsülte ettiği hastalardan Meropenem başlama uygunsuzluğu **%25**'tir. (N:68 n:17)


Dr. H.Ö: **%63** (N:19, n:12)

Dr. Ş.K ve Dr. Ö.E: **%8** (N:48, n:4)


Enfeksiyon Hastalıkları'nın Konsülte etmediği hastalardan, Meropenem başlama uygunsuzluğu **%54**'tür. (N:35 n:19)

Kinolon Grubu Antibiyotik Tüketimi (DDD) 2015-2016-2017-2018-2019


Kinolon Grubu Antibiyotiklerin Yıl Bazında Tüketimi DDD (2015-2016-2017-2018-2019)



Antibiyotiklere baęlı advers etkiler
(2015-2016-2017-2018-2019)



Antibiyotiklere baęlı advers etkiler
(2015-2016-2017-2018-2019)



Advers Etki Bildirimleri

